Yong Yu Sells 9,683 Shares of Genelux (NASDAQ:GNLX) Stock

Genelux Corporation (NASDAQ:GNLX) insider Yong Yu sold 9,683 shares of the stock in a transaction on Monday, August 31st. The stock was sold at an average price of $2.75, for a total transaction of $26,628.25. Following the transaction, the insider directly owned 258,688 shares in the company, valued at $711,392. The trade was a 3.61% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link.

Yong Yu also recently made the following trade(s):

• On Tuesday, August 4th, Yong Yu sold 653 shares of Genelux stock. The shares were sold at an average price of $2.94, for a total value of $1,919.82.

Genelux Price Performance

Shares of NASDAQ:GNLX opened at $2.52 on Friday. Genelux Corporation has a fifty-two week low of $2.29 and a fifty-two week high of $8.53. The business has a 50-day moving average of $2.82 and a two-hundred day moving average of $2.78. The stock has a market capitalization of $114.00 million, a P/E ratio of -2.93 and a beta of 0.57.

Genelux (NASDAQ:GNLX) last issued its quarterly earnings data on Thursday, August 13th. The company reported ($0.21) EPS for the quarter, missing analysts’ consensus estimates of ($0.20) by ($0.01). As a group, research analysts expect that Genelux Corporation will post -0.81 EPS for the current fiscal year.

Institutional Investors Weigh In On Genelux

A number of institutional investors have recently bought and sold shares of the business. Jefferies Financial Group Inc. acquired a new position in shares of Genelux in the 4th quarter valued at $48,000. GSA Capital Partners LLP bought a new position in Genelux during the second quarter worth about $35,000. Squarepoint Ops LLC bought a new position in Genelux during the fourth quarter worth about $52,000. Balyasny Asset Management L.P. acquired a new stake in Genelux during the fourth quarter valued at approximately $94,000. Finally, Align Financial LLC acquired a new stake in Genelux during the fourth quarter valued at approximately $123,000. Institutional investors and hedge funds own 37.33% of the company’s stock.

Analysts Set New Price Targets

Several brokerages recently commented on GNLX. Benchmark reiterated a “speculative buy” rating on shares of Genelux in a report on Tuesday, August 18th. Wall Street Zen upgraded shares of Genelux from a “strong sell” rating to a “sell” rating in a report on Sunday, August 23rd. Finally, Weiss Ratings restated a “sell (e+)” rating on shares of Genelux in a report on Friday, July 17th. Three investment analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and a consensus price target of $18.00.

About Genelux

Genelux Corporation (NASDAQ:GNLX) is a clinical-stage biotechnology company focused on the development of oncolytic virus immunotherapies. Built on a proprietary vaccinia virus platform, the company’s programs are designed to selectively infect and destroy cancer cells while stimulating a systemic immune response. Genelux’s lead candidate, pexastimogene devacirepvec (GL-ONC1), is being evaluated in multiple indications, including peritoneal malignancies and head and neck cancers, where it is administered either intraperitoneally or systemically depending on the trial design.

Genelux’s pipeline leverages its experience with the GL-ONC1 construct to explore combination strategies with chemotherapy and immuno-oncology agents.